Navigation Links
Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke

An experimental drug called 3K3A-APC appears to reduce brain damage, eliminate brain hemorrhaging and improve motor skills in older stroke-afflicted mice and stroke-afflicted rats with comorbid conditions such as hypertension, according to a new study from Keck Medicine of the University of Southern California (USC).

The study, which appears online today in the journal Stroke, provides additional evidence that 3K3A-APC may be used as a therapy for stroke in humans, either alone or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator). Clinical trials to test the drug's efficacy in people experiencing acute ischemic stroke are expected to begin recruiting patients in the U.S. in 2014.

"Currently, tPA is the best treatment for stroke caused by a blocked artery, but it must be administered within three hours after stroke onset to be effective," said Berislav V. Zlokovic, M.D., Ph.D., director of the Zilkha Neurogenetic Institute (ZNI) at the Keck School of Medicine of USC and the study's lead investigator. "Because of this limited window, only a small fraction of those who suffer a stroke reach the hospital in time to be considered for tPA. Our studies show that 3K3A-APC extends tPA's therapeutic window and counteracts tPA's tendency to induce bleeding in the brains of animals having a stroke."

Zlokovic is the scientific founder of ZZ Biotech, a Houston-based biotechnology company he co-founded with USC benefactor Selim Zilkha to develop biological treatments for stroke and other neurological ailments. ZZ Biotech's 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C (APC), which plays a role in the regulation of blood clotting and inflammation. 3K3A-APC has been shown to have a protective effect on the lining of blood vessels in rodent brains, which appears to help prevent bleeding caused by tPA.

In collaboration with Cedars-Sinai Medical Center and The Scripps Research Institute, Zlokovic and his team gave tPA alone and in combination with 3K3A-APC to mature female mice and male hypertensive rats four hours after stroke. They also gave 3K3A-APC in regular intervals up to seven days after stroke. They measured the amount of brain damage, bleeding and motor ability of the rodents up to four weeks after stroke.

The researchers found that, under those conditions, tPA therapy alone caused bleeding in the brain and did not reduce brain damage or improve motor ability when compared to the control. The combination of tPA and 3K3A-APC, however, reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor ability.

"Scientists all around the globe are studying potential stroke therapies, but very few have the robust preclinical data package that 3K3A-APC has," said Kent Pryor, Ph.D., M.B.A., ZZ Biotech's chief operating officer. "The results from Dr. Zlokovic's studies have been very promising."

Zlokovic's team previously reported similar results in young, healthy male rodents. A Phase 1 trial testing the safety of 3K3A-APC in healthy human volunteers, led by study co-author Patrick D. Lyden, M.D., of Cedars-Sinai, concluded in February.

"We now have opened an investigational new drug application at the FDA to conduct a Phase 2 clinical trial of 3K3A-APC in patients experiencing acute ischemic stroke," said Joe Romano, CEO and president of ZZ Biotech. "We are excited to see 3K3A-APC move from healthy volunteers to real patients suffering from this terrible disease."


Contact: Alison Trinidad
University of Southern California - Health Sciences

Related biology news :

1. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
2. Experimental drug combination selectively destroys lymphoma cells
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
5. New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass.
6. AMP joins the Federation of American Societies for Experimental Biology
7. Soy-based S-equol supplement reduces metabolic syndrome risk factors
8. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Hot sauce ingredient reduces beer belly fat as a weight-loss surgery alternative
11. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
Post Your Comments:
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
Breaking Biology Technology: